Acetaminophen (APAP)-induced liver injury is the most frequent cause of acute liver failure in the US and many other countries. APAP produces liver cell death by a sequence of events that requires the early formation of a reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), a subsequent phase where adducts of cellular and mitochondrial proteins are formed, and a final phase where these adducts trigger mitochondrial dysfunction and necrotic cell death. Administration of N-acetyl cysteine (NAC) at the early phase can efficiently increase intracellular glutathione levels and scavenge NAPQI and protect against liver injury. However, patients frequently present only after this phase is over and there are no treatments available to prevent liver injury in the subsequent phases of pathogenesis. Our recent work has shown that cell survival in the later injury phases is dependent on the autophagy pathway, presumably because of the autophagic removal of damaged mitochondria. Our preliminary data show that p62/SQSTM1 (hereafter referred to as p62) is recruited both to APAP-AD and damaged mitochondria and it induces their selective removal by autophagy. Our published data also show that liver-specific Atg5 knockout mice are resistant to APAP-induced liver injury even though they have defective autophagy. In this case, resistance results from the accumulation of p62 which results in persistent activation of the antioxidant transcription factor Nrf2. These data suggest that both autophagic and non-autophagic roles of p62 are involved in protecting against APAP-induced liver injury. The central hypothesis of this proposal is that selective p62-mediated autophagic removal of APAP-AD and damaged mitochondria and non-autophagic activation of Nrf2 are crucial to protect against the later phase of APAP-induced liver injury. To examine our hypothesis, three specific aims are proposed: 1) determine the central role of p62 in autophagic removal of APAP-AD and damaged mitochondria in vivo and in primary mouse and human hepatocytes, 2) determine the autophagic and non-autophagic role of p62 in protection against APAP-induced liver injury, and 3) determine the induction of p62-mediated autophagy and non- autophagic activation of Nrf2 can promote the recovery from APAP-induced liver injury in a post-APAP treatment mouse model. Results from this study will lead to the in-depth understanding of p62-mediated autophagy and non-autophagic mechanisms in protecting against cell injury in the late phase of APAP-induced pathogenesis, which no treatment is available and NAC treatment is no longer effective. Ultimately, such knowledge has the potential of identifying novel therapeutic approaches for treating the late phase of APAP- induced liver injury and liver failure.

Public Health Relevance

Acetaminophen (APAP)-induced liver injury is the most frequent cause of acute liver failure of any etiology in the US representing about 50% of all cases. There is an urgent need to develop novel therapeutic strategies that could be effective beyond the early metabolism phase because the current treatment N-acetylcysteine (NAC) is less effective due to the late presentation of most patients. Based on our previous novel findings and the preliminary data, we propose to study the molecular mechanisms of p62-mediated selective autophagy and non-autophagic Nrf2 activation in the clearance of APAP protein adducts and damaged mitochondria in mouse and human hepatocytes and in vivo in order to identify novel therapeutic targets that could be used to attenuate cell death at later stages after the overdose, which would prevent liver failure and promote recovery of the patient.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Serrano, Jose
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas
Schools of Medicine
Kansas City
United States
Zip Code
Woolbright, Benjamin L; Jaeschke, Hartmut (2016) Role of the Inflammasome in Acetaminophen-induced Liver Injury and Acute Liver Failure. J Hepatol :
Wang, Shaogui; Ni, Hong-Min; Dorko, Kenneth et al. (2016) Increased hepatic receptor interacting protein kinase 3 expression due to impaired proteasomal functions contributes to alcohol-induced steatosis and liver injury. Oncotarget 7:17681-98
Weemhoff, James L; Woolbright, Benjamin L; Jenkins, Rosalind E et al. (2016) Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic hepatitis. Liver Int :
Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203
Hu, Jiangting; Ramshesh, Venkat K; McGill, Mitchell R et al. (2016) Low Dose Acetaminophen Induces Reversible Mitochondrial Dysfunction Associated with Transient c-Jun N-Terminal Kinase Activation in Mouse Liver. Toxicol Sci 150:204-15
Maes, Michaël; McGill, Mitchell R; da Silva, Tereza Cristina et al. (2016) Connexin32: a mediator of acetaminophen-induced liver injury? Toxicol Mech Methods 26:88-96
McGill, Mitchell R; Kennon-McGill, Stefanie; Durham, Dianne et al. (2016) Hearing, reactive metabolite formation, and oxidative stress in cochleae after a single acute overdose of acetaminophen: an in vivo study. Toxicol Mech Methods 26:104-11
Li, Yuan; Ding, Wen-Xing (2016) A Gene Transcription Program Decides the Differential Regulation of Autophagy by Acute Versus Chronic Ethanol? Alcohol Clin Exp Res 40:47-9
Li, Yuan; McGreal, Steven; Zhao, Jean et al. (2016) A cell-based quantitative high-throughput image screening identified novel autophagy modulators. Pharmacol Res 110:35-49
Woolbright, Benjamin L; Jaeschke, Hartmut (2016) Noncoding RNAs as therapeutics for acetaminophen-induced liver injury. Stem Cell Investig 3:54

Showing the most recent 10 out of 53 publications